SREBP1 interaction with prelamin A forms: A pathogenic mechanism for lipodystrophic laminopathies

Nadir M. Maraldi, Cristina Capanni, Giovanna Lattanzi, Daria Camozzi, Andrea Facchini, Francesco A. Manzoli

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The understanding of a common complex phenotype such as insulin resistance can be favored by evaluation of monogenic syndromes. Clinical definition, pathogenesis, and therapeutic strategies for the insulin resistance syndrome can thus be improved by the characterization at the molecular genetic level of monogenic forms of lipodystrophies. Among them, the Dunnigan-type familial partial lipodystrophy (FPLD), the mandibuloacral dysplasia (MADA), the syndromes of partial lipodystrophy with cardiomyopathy, the Hutchinson-Gilford progeria (HGPS), and the atypical Werner's syndrome (WS) are due to mutations of the gene coding for the nuclear lamin A/C. FPLD has been shown to associate with altered processing of the lamin A precursor protein, known as prelamin A. The molecular mechanism causing the lipodystrophy phenotype downstream of prelamin A accumulation resides in an anomalous interaction of the nuclear lamina protein with the transcription factor sterol regulatory element binding protein 1 (SREBP1), which slows down the nuclear import of SREBP1. The ultimate effect of sustained prelamin A accumulation in adipocytes is a reduced transcription and possibly activation of the transcription factor peroxisome proliferator-activated receptor (PPARγ) which is involved in differentiation. In the present study, we show that prelamin A accumulates in the nucleus and establishes a strong interaction with SREBP1. We further investigate the interplay between SREBP1 and farnesylated, non-farnesylated or pathogenic prelamin A forms in transfected adipocytes. The obtained results support the view of a major role of prelamin A accumulation in the pathogenesis of LMNA-linked adipose tissue disorders. Furthermore, we found that treatment with the PPARγ ligand troglitazone (TZD) is able to rescue the adipogenic program. Since FPLD recapitulates the essential metabolic abnormalities of the common insulin resistance syndrome, the beneficial effects of TZD on monogenic lipodystrophies might provide a clue as to the future treatment strategies also for the common syndrome of insulin resistance.

Original languageEnglish
Pages (from-to)209-223
Number of pages15
JournalAdvances in Enzyme Regulation
Volume48
Issue number1
DOIs
Publication statusPublished - 2008

Fingerprint

Sterol Regulatory Element Binding Protein 1
Lipodystrophy
Familial Partial Lipodystrophy
Insulin Resistance
Insulin
Peroxisome Proliferator-Activated Receptors
troglitazone
Adipocytes
Transcription Factors
Progeria
Nuclear Lamina
Werner Syndrome
Lamin Type A
Phenotype
Cell Nucleus Active Transport
Transcription
Nuclear Proteins
prelamin A
Cardiomyopathies
Transcriptional Activation

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

SREBP1 interaction with prelamin A forms : A pathogenic mechanism for lipodystrophic laminopathies. / Maraldi, Nadir M.; Capanni, Cristina; Lattanzi, Giovanna; Camozzi, Daria; Facchini, Andrea; Manzoli, Francesco A.

In: Advances in Enzyme Regulation, Vol. 48, No. 1, 2008, p. 209-223.

Research output: Contribution to journalArticle

Maraldi, Nadir M. ; Capanni, Cristina ; Lattanzi, Giovanna ; Camozzi, Daria ; Facchini, Andrea ; Manzoli, Francesco A. / SREBP1 interaction with prelamin A forms : A pathogenic mechanism for lipodystrophic laminopathies. In: Advances in Enzyme Regulation. 2008 ; Vol. 48, No. 1. pp. 209-223.
@article{e63826494a9d414680c7b9d3730af879,
title = "SREBP1 interaction with prelamin A forms: A pathogenic mechanism for lipodystrophic laminopathies",
abstract = "The understanding of a common complex phenotype such as insulin resistance can be favored by evaluation of monogenic syndromes. Clinical definition, pathogenesis, and therapeutic strategies for the insulin resistance syndrome can thus be improved by the characterization at the molecular genetic level of monogenic forms of lipodystrophies. Among them, the Dunnigan-type familial partial lipodystrophy (FPLD), the mandibuloacral dysplasia (MADA), the syndromes of partial lipodystrophy with cardiomyopathy, the Hutchinson-Gilford progeria (HGPS), and the atypical Werner's syndrome (WS) are due to mutations of the gene coding for the nuclear lamin A/C. FPLD has been shown to associate with altered processing of the lamin A precursor protein, known as prelamin A. The molecular mechanism causing the lipodystrophy phenotype downstream of prelamin A accumulation resides in an anomalous interaction of the nuclear lamina protein with the transcription factor sterol regulatory element binding protein 1 (SREBP1), which slows down the nuclear import of SREBP1. The ultimate effect of sustained prelamin A accumulation in adipocytes is a reduced transcription and possibly activation of the transcription factor peroxisome proliferator-activated receptor (PPARγ) which is involved in differentiation. In the present study, we show that prelamin A accumulates in the nucleus and establishes a strong interaction with SREBP1. We further investigate the interplay between SREBP1 and farnesylated, non-farnesylated or pathogenic prelamin A forms in transfected adipocytes. The obtained results support the view of a major role of prelamin A accumulation in the pathogenesis of LMNA-linked adipose tissue disorders. Furthermore, we found that treatment with the PPARγ ligand troglitazone (TZD) is able to rescue the adipogenic program. Since FPLD recapitulates the essential metabolic abnormalities of the common insulin resistance syndrome, the beneficial effects of TZD on monogenic lipodystrophies might provide a clue as to the future treatment strategies also for the common syndrome of insulin resistance.",
author = "Maraldi, {Nadir M.} and Cristina Capanni and Giovanna Lattanzi and Daria Camozzi and Andrea Facchini and Manzoli, {Francesco A.}",
year = "2008",
doi = "10.1016/j.advenzreg.2007.11.003",
language = "English",
volume = "48",
pages = "209--223",
journal = "Advances in Enzyme Regulation",
issn = "0065-2571",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - SREBP1 interaction with prelamin A forms

T2 - A pathogenic mechanism for lipodystrophic laminopathies

AU - Maraldi, Nadir M.

AU - Capanni, Cristina

AU - Lattanzi, Giovanna

AU - Camozzi, Daria

AU - Facchini, Andrea

AU - Manzoli, Francesco A.

PY - 2008

Y1 - 2008

N2 - The understanding of a common complex phenotype such as insulin resistance can be favored by evaluation of monogenic syndromes. Clinical definition, pathogenesis, and therapeutic strategies for the insulin resistance syndrome can thus be improved by the characterization at the molecular genetic level of monogenic forms of lipodystrophies. Among them, the Dunnigan-type familial partial lipodystrophy (FPLD), the mandibuloacral dysplasia (MADA), the syndromes of partial lipodystrophy with cardiomyopathy, the Hutchinson-Gilford progeria (HGPS), and the atypical Werner's syndrome (WS) are due to mutations of the gene coding for the nuclear lamin A/C. FPLD has been shown to associate with altered processing of the lamin A precursor protein, known as prelamin A. The molecular mechanism causing the lipodystrophy phenotype downstream of prelamin A accumulation resides in an anomalous interaction of the nuclear lamina protein with the transcription factor sterol regulatory element binding protein 1 (SREBP1), which slows down the nuclear import of SREBP1. The ultimate effect of sustained prelamin A accumulation in adipocytes is a reduced transcription and possibly activation of the transcription factor peroxisome proliferator-activated receptor (PPARγ) which is involved in differentiation. In the present study, we show that prelamin A accumulates in the nucleus and establishes a strong interaction with SREBP1. We further investigate the interplay between SREBP1 and farnesylated, non-farnesylated or pathogenic prelamin A forms in transfected adipocytes. The obtained results support the view of a major role of prelamin A accumulation in the pathogenesis of LMNA-linked adipose tissue disorders. Furthermore, we found that treatment with the PPARγ ligand troglitazone (TZD) is able to rescue the adipogenic program. Since FPLD recapitulates the essential metabolic abnormalities of the common insulin resistance syndrome, the beneficial effects of TZD on monogenic lipodystrophies might provide a clue as to the future treatment strategies also for the common syndrome of insulin resistance.

AB - The understanding of a common complex phenotype such as insulin resistance can be favored by evaluation of monogenic syndromes. Clinical definition, pathogenesis, and therapeutic strategies for the insulin resistance syndrome can thus be improved by the characterization at the molecular genetic level of monogenic forms of lipodystrophies. Among them, the Dunnigan-type familial partial lipodystrophy (FPLD), the mandibuloacral dysplasia (MADA), the syndromes of partial lipodystrophy with cardiomyopathy, the Hutchinson-Gilford progeria (HGPS), and the atypical Werner's syndrome (WS) are due to mutations of the gene coding for the nuclear lamin A/C. FPLD has been shown to associate with altered processing of the lamin A precursor protein, known as prelamin A. The molecular mechanism causing the lipodystrophy phenotype downstream of prelamin A accumulation resides in an anomalous interaction of the nuclear lamina protein with the transcription factor sterol regulatory element binding protein 1 (SREBP1), which slows down the nuclear import of SREBP1. The ultimate effect of sustained prelamin A accumulation in adipocytes is a reduced transcription and possibly activation of the transcription factor peroxisome proliferator-activated receptor (PPARγ) which is involved in differentiation. In the present study, we show that prelamin A accumulates in the nucleus and establishes a strong interaction with SREBP1. We further investigate the interplay between SREBP1 and farnesylated, non-farnesylated or pathogenic prelamin A forms in transfected adipocytes. The obtained results support the view of a major role of prelamin A accumulation in the pathogenesis of LMNA-linked adipose tissue disorders. Furthermore, we found that treatment with the PPARγ ligand troglitazone (TZD) is able to rescue the adipogenic program. Since FPLD recapitulates the essential metabolic abnormalities of the common insulin resistance syndrome, the beneficial effects of TZD on monogenic lipodystrophies might provide a clue as to the future treatment strategies also for the common syndrome of insulin resistance.

UR - http://www.scopus.com/inward/record.url?scp=51349153839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51349153839&partnerID=8YFLogxK

U2 - 10.1016/j.advenzreg.2007.11.003

DO - 10.1016/j.advenzreg.2007.11.003

M3 - Article

C2 - 18155670

AN - SCOPUS:51349153839

VL - 48

SP - 209

EP - 223

JO - Advances in Enzyme Regulation

JF - Advances in Enzyme Regulation

SN - 0065-2571

IS - 1

ER -